Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Makes Major Push To Stem Increase In MDR-TB Risk

This article was originally published in PharmAsia News

Executive Summary

India plans to provide diagnostics equipment and treatments in an effort to meet a target of getting control by 2010 of multi-drug resistant tuberculosis in the country. The TB type is resistant to isoniazid and rifampicin, the best first-line drugs for fighting the disease. The rate of MDR-TB cases in India is not necessarily increasing any faster than in other developing countries, but is considered more troublesome in the country because of its huge population. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel